Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The Bergamo Kidney Transplant Program.

Norberto Perico1, Paolo Cravedi, Piero Ruggenenti

  • 1Department of Medicine and Transplantation, Ospedali Riuniti - Mario Negri Institute for Pharmacological Research, Bergamo, Italy.

Clinical Transplants
|April 12, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanisms of SGLT inhibitor action and physiological mediators: systematic review and protocol for the MOSAIC collaborative meta-analysis.

BMJ open·2026
Same author

Deep learning-driven MRI for accurate brain volumetry in murine models of neurodegenerative diseases.

Frontiers in neuroscience·2025
Same author

Randomized Trial of Dapagliflozin in Patients With Nondiabetic Stage 4 CKD.

Kidney international reports·2025
Same author

A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib.

Clinical pharmacology and therapeutics·2025
Same author

Lost in translation: rethinking animal models of progressive MS (an industry perspective).

Multiple sclerosis and related disorders·2025
Same journal

Clinical Relevance of Donor-Specific IgM Antibodies in HLA Incompatible Renal Transplantation: A Retrospective Single-Center Study.

Clinical transplants·2017
Same journal

Influenza Immunization and the Generation of Anti-HLA and Anti-MICA Antibodies in Patients with Renal Failure and in Kidney Transplant Recipients.

Clinical transplants·2017
Same journal

From Accurate Assessment of Anti-HLA Antibody MFI to Complement-Binding Assays.

Clinical transplants·2017
Same journal

Post-transplant Desensitization for Deceased Donor Kidney Transplant Recipients: A Single Center Experience.

Clinical transplants·2017
Same journal

Acute Rejection in 6-Antigen HLA-Matched Kidney Transplant Recipients: Risk Factors and Outcomes from the Wisconsin Allograft Recipient Database (WisARD).

Clinical transplants·2017
Same journal

C1q Donor-Specific Antibody Associates with Post-transplant Biopsy Findings in Highly- Sensitized Kidney Transplant Recipients.

Clinical transplants·2017
See all related articles

This study explores optimizing kidney transplant outcomes by expanding donor organ pools and refining immunosuppression strategies. Findings suggest personalized immunosuppression and utilizing marginal donor kidneys can improve patient quality of life.

Area of Science:

  • Nephrology
  • Transplant Medicine
  • Immunology

Background:

  • Increasing demand for transplantable organs necessitates expanding donor pools.
  • Chronic kidney function decline and graft loss limit long-term transplant success.
  • Side effects of immunosuppressive medications pose significant challenges.

Purpose of the Study:

  • To optimize kidney graft outcomes and recipient quality of life.
  • To expand the pool of deceased donor organs for transplantation.
  • To refine immunosuppressive regimens and manage drug-related side effects.

Main Methods:

  • Established a dual kidney transplant program for donors over 60 years old.
  • Utilized pretransplant histology protocols and scoring systems.

Related Experiment Videos

  • Investigated per-protocol biopsies to guide immunosuppression adjustments.
  • Studied pharmacokinetic monitoring of immunosuppressive agents like mycophenolic acid (MPA).
  • Explored management strategies for delayed graft function in marginal donor kidneys.
  • Developed a multiorgan transplant program for rare diseases like hemolytic uremic syndrome (HUS).

    • Main Results:

    • Dual kidney transplantation from older donors showed promising outcomes.
    • Reduced calcineurin inhibitor (CsA) doses with low trough levels maintained graft function and prevented rejection.
    • Novel induction therapies minimized maintenance immunosuppression, reducing corticosteroid use.
    • Per-protocol biopsies safely guided immunosuppression changes, lowering drug toxicity.
    • Pharmacokinetic monitoring of MPA and sirolimus is advised for personalized management.
    • Strategies for managing delayed graft function in marginal kidneys were investigated.

    Conclusions:

    • Optimizing immunosuppression through per-protocol biopsies and pharmacokinetic monitoring improves long-term kidney transplant outcomes.
    • Expanding the use of marginal donor organs, including those from older donors, can increase organ availability.
    • Personalized immunosuppressive strategies are crucial for minimizing drug toxicity and enhancing graft survival.
    • Multidisciplinary approaches are essential for managing complex cases, such as HUS requiring multiorgan transplantation.